These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 28167571

  • 1. Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.
    Walko CM, Aubert RE, La-Beck NM, Clore G, Herrera V, Kourlas H, Epstein RS, McLeod HL.
    Oncologist; 2017 Feb; 22(2):208-212. PubMed ID: 28167571
    [Abstract] [Full Text] [Related]

  • 2. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
    Feldt S, Schüssel K, Quinzler R, Franzmann A, Czeche S, Ludwig WD, Schulz M.
    Eur J Cancer; 2012 May; 48(7):974-81. PubMed ID: 22382202
    [Abstract] [Full Text] [Related]

  • 3. Thyroid dysfunction in patients treated with sunitinib or sorafenib.
    Clemons J, Gao D, Naam M, Breaker K, Garfield D, Flaig TW.
    Clin Genitourin Cancer; 2012 Dec; 10(4):225-31. PubMed ID: 23017335
    [Abstract] [Full Text] [Related]

  • 4. Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
    Shu M, Zai X, Zhang B, Wang R, Lin Z.
    PLoS One; 2016 Dec; 11(1):e0147048. PubMed ID: 26784451
    [Abstract] [Full Text] [Related]

  • 5. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
    Calvani N, Morelli F, Leo S, Orlando L, Lombardi L, Gnoni A, Cinefra M, Maiello E, Lorusso V, Cinieri S.
    Med Oncol; 2012 Sep; 29(3):1908-13. PubMed ID: 21858552
    [Abstract] [Full Text] [Related]

  • 6. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W, Yuan YC, Li MY, Kong W, Dong BJ, Chen YH, Zhang J, Xue W, Huang YR, Zhou LX, Huang JW.
    Zhonghua Zhong Liu Za Zhi; 2018 May 23; 40(5):384-389. PubMed ID: 29860767
    [Abstract] [Full Text] [Related]

  • 7. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    Kitajima K, Takahashi S, Maeda T, Yoshikawa T, Ohno Y, Fujii M, Miyake H, Fujisawa M, Sugimura K.
    Eur J Radiol; 2012 Sep 23; 81(9):2060-5. PubMed ID: 21724350
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
    Jang S, Zheng C, Tsai HT, Fu AZ, Barac A, Atkins MB, Freedman AN, Minasian L, Potosky AL.
    Cancer; 2016 Jan 01; 122(1):124-30. PubMed ID: 26439451
    [Abstract] [Full Text] [Related]

  • 9. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
    Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G.
    Nat Rev Clin Oncol; 2009 Apr 01; 6(4):219-28. PubMed ID: 19333228
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, Zhou W, Shen Z.
    Urol Oncol; 2013 Nov 01; 31(8):1800-5. PubMed ID: 22658883
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J.
    Oncotarget; 2016 May 10; 7(19):27044-54. PubMed ID: 26894858
    [Abstract] [Full Text] [Related]

  • 12. Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
    Cai W, Kong W, Dong B, Zhang J, Chen Y, Xue W, Huang Y, Zhou L, Huang J.
    Chin J Cancer; 2017 Aug 08; 36(1):64. PubMed ID: 28789709
    [Abstract] [Full Text] [Related]

  • 13. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
    Funakoshi T, Latif A, Galsky MD.
    J Hum Hypertens; 2013 Oct 08; 27(10):601-11. PubMed ID: 23636006
    [Abstract] [Full Text] [Related]

  • 14. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC.
    Cancer; 2011 Feb 01; 117(3):534-44. PubMed ID: 20845482
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hypothyroidism during treatment with tyrosine kinase inhibitors.
    Zygulska AL, Krzemieniecki K, Sowa-Staszczak A.
    Endokrynol Pol; 2012 Feb 01; 63(4):302-6. PubMed ID: 22933166
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS.
    Eur Urol; 2015 Nov 01; 68(5):837-47. PubMed ID: 25952317
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.